Characteristics of patients with spontaneous mixed RhD phenotype
| Patient . | Sex . | Age, y* . | Diagnosis . | RH genotype† . | Blood group phenotype‡ . | D-positive RBCs, % . | Number of D sites per D-positive RBCs§ . | Follow-up, mo║ . | Dynamics of D antigen positivity over follow-up interval . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rh . | Duffy . | ||||||||||||||
| D . | C . | E . | c . | e . | Fya . | Fyb . | |||||||||
| 1 | M | 63 | Idiopathic osteomyelofibrosis | CcDdee | ± | ± | − | + | + | + | + | 56 | 11182 | 44 | Complete loss |
| 2 | M | 56 | Rheumatoid arthritis | CcDdee | ± | ± | − | + | + | − | + | 67 | 12073 | 52 | Stable |
| 3 | M | 60 | Anal fistula | CcDdee | ± | ± | − | + | + | + | − | 46 | 12578 | 40 | Stable |
| 4 | F | 86 | Essential thrombocythemia | CcDdee | ± | ± | − | + | + | − | + | 85 | 9838 | 5 | Stable |
| 5 | F | 33 | Uterus myomatosus | CcDdee | ± | ± | − | + | + | + | ± | 81 | 11380 | 24 | Stable |
| 6 | M | 67 | Acute myelogenous leukemia | CcDvardee¶ | ±w | ± | − | + | + | − | + | 56 | 4419 | 13 | Progressive loss |
| 7 | F | 43 | Psychosis | ccDdEe | ± | − | ± | + | + | + | + | 22 | nd | 65 | Progressive loss |
| 8 | F | 78 | Colon carcinoma | CcDdee | ± | ± | − | + | + | − | + | nd | nd | 33 | Complete loss |
| 9 | F | 86 | Leg vein thrombosis | CcDdee | ± | ± | − | + | + | − | + | 40 | 10950 | 12 | Stable |
| Patient . | Sex . | Age, y* . | Diagnosis . | RH genotype† . | Blood group phenotype‡ . | D-positive RBCs, % . | Number of D sites per D-positive RBCs§ . | Follow-up, mo║ . | Dynamics of D antigen positivity over follow-up interval . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rh . | Duffy . | ||||||||||||||
| D . | C . | E . | c . | e . | Fya . | Fyb . | |||||||||
| 1 | M | 63 | Idiopathic osteomyelofibrosis | CcDdee | ± | ± | − | + | + | + | + | 56 | 11182 | 44 | Complete loss |
| 2 | M | 56 | Rheumatoid arthritis | CcDdee | ± | ± | − | + | + | − | + | 67 | 12073 | 52 | Stable |
| 3 | M | 60 | Anal fistula | CcDdee | ± | ± | − | + | + | + | − | 46 | 12578 | 40 | Stable |
| 4 | F | 86 | Essential thrombocythemia | CcDdee | ± | ± | − | + | + | − | + | 85 | 9838 | 5 | Stable |
| 5 | F | 33 | Uterus myomatosus | CcDdee | ± | ± | − | + | + | + | ± | 81 | 11380 | 24 | Stable |
| 6 | M | 67 | Acute myelogenous leukemia | CcDvardee¶ | ±w | ± | − | + | + | − | + | 56 | 4419 | 13 | Progressive loss |
| 7 | F | 43 | Psychosis | ccDdEe | ± | − | ± | + | + | + | + | 22 | nd | 65 | Progressive loss |
| 8 | F | 78 | Colon carcinoma | CcDdee | ± | ± | − | + | + | − | + | nd | nd | 33 | Complete loss |
| 9 | F | 86 | Leg vein thrombosis | CcDdee | ± | ± | − | + | + | − | + | 40 | 10950 | 12 | Stable |
RBC indicates red blood cell; ±, positive/negative mixed-field agglutination; −, negative; +, positive; ± w, weak positive/negative mixed-field; and nd, not determined.
Age at initial recognition of mixed RhD status.
RH genotype and RHD zygosity as determined from blood DNA samples.
In all patients, normal unmixed ABO, MNS, P, Lutheran, Kell, and Kidd blood group phenotypes were found.
D antigen densities of RH genotype–matched CcDdee and CcDvardee (D category IV type 4) control samples were 10724 and 4327 D sites per red cell, respectively.
Time interval from initial serologic recognition of mixed RhD status to its latest determination; during this time, no patient received transfusions.
Patient 6 (CcDvardee) displayed a partial D variant, D category IV type 4.